Empalieva-25 Empagliflozin Tablets 25mg

Empalieva-25 Empagliflozin Tablets 25mg Description:

Empalieva-25 contains Empagliflozin, an oral anti-diabetic medication belonging to the class of SGLT2 inhibitors (Sodium-Glucose Co-Transporter 2 inhibitors). It helps lower blood sugar levels by preventing the reabsorption of glucose in the kidneys, leading to glucose being excreted in the urine.

In addition to improving blood sugar control in adults with type 2 diabetes mellitus, Empagliflozin also provides cardiovascular and renal benefits, making it a preferred option in patients with heart failure or diabetic kidney disease.

Uses:

• Management of type 2 diabetes mellitus (as monotherapy or in combination)
• Reduces risk of cardiovascular death in adults with type 2 diabetes and heart disease
• Used to manage heart failure with reduced ejection fraction (HFrEF)
• May slow the progression of diabetic kidney disease

Side Effects:

Common side effects may include:

• Increased urination
• Thirst
• Genital infections (yeast infections)
• Urinary tract infections (UTIs)
• Dizziness
• Low blood sugar (when used with other anti-diabetic drugs)

Serious side effects can include:

• Dehydration
• Ketoacidosis (rare but serious)
• Kidney problems
• Serious genital infections (e.g., Fournier’s gangrene)

Patients should stay well-hydrated and monitor for signs of infection or dehydration.

Dosage:

To be taken orally once daily, with or without food.
Do not self-adjust dosage. Take only as prescribed by your doctor.